Indomethacin in the treatment of idiopathic minimal lesion nephrotic syndrome.
Ten patients with idiopathic minimal lesion nephrotic syndrome were treated with indomethacin. Nine patients received the drug for five weeks and one patient for nine weeks. Indomethacin was administered in a dose of 1 mg/kg/day during the first week and 2 mg/kg/day, thereafter. At the end of the study, nine patients remained edematous and all had a urinary protein excretion greater than 50 mg/kg/day, within the nephrotic range. Indomethacin did not change the course of the disease and its use in the treatment of IMLNS is not advised.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy*; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology
D007213:Indomethacin